Penicillin Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, China - Size and Forecast 2024-2028

Penicillin Market Forecast 2024-2028

The global penicillin market size is estimated to grow by USD 2.82 billion at a CAGR of 5.4% between 2023 and 2028. The rising prevalence of infectious diseases, driven by factors such as population growth, urbanization, and globalization, is driving market growth by increasing the demand for antibiotics for the treatment of bacterial infections. The growing awareness of various diseases and their treatment, driven by efforts from healthcare organizations and governments to educate the public about healthcare issues, is also boosting market expansion by increasing the demand for effective antibiotics. Additionally, special regulatory designations driving the quality of penicillin, such as quality standards set by regulatory authorities and organizations, are driving market growth by ensuring the safety and efficacy of penicillin products.

Early detection of infectious diseases is crucial to minimize severe damage to the body. The heightened awareness of infections and available treatments, such as penicillin, drives early-stage treatment, preventing disease escalation. Various programs contribute to increased health awareness, like European Antibiotic Awareness Day on November 18, promoting judicious antibiotic use. Initiatives like Healthy People 2020 by the Hospital for Special Surgery and events such as World Hand Hygiene Day, National Infection Control Week, and World Pneumonia Day enhance infection awareness. Organizations like the Amanda Young Foundation focus on preventing meningococcal disease deaths and organizing activities to raise awareness. Such programs elevate disease awareness, encouraging more individuals to seek treatment and fostering the market's growth during the forecast period.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Market Segmentation

The market encompasses various segments within the pharmaceutical industry, focusing on the production and distribution of antibiotic drugs. Production facilities play a critical role in ensuring the uninterrupted supply of Penicillin derivatives, especially amidst interruptions in services caused by factors such as the COVID-19 pandemic. Penicillin drugs target bacterial infections, including pneumonia, respiratory tract infections, scarlet fever, ear infections, skin infections, gum infections, mouth infections, throat infections, and even syphilis. Research and development activities continue to drive innovation in the field, aiming to combat infectious diseases effectively. Additionally, the market includes both branded and generic drugs to cater to diverse healthcare needs.

By Source 

The market share growth by the semisynthetic segment will be significant during the forecast period. Semisynthetic penicillin is typically produced by hydrolysis of naturally occurring antibiotics (such as penicillin G) and by further amidation of naturally or mutagenic antibiotic nuclei with various carboxylic acid donor chains. Semisynthetic penicillin has increased coverage and efficacy against a broad spectrum of organisms, including the majority of streptococcal, staphylococci, aerobic Gram-negative organisms, and a large number of anaerobes.

Get a glance at the market contribution of various segments Download PDF Sample

The semisynthetic was the largest segment and was valued at USD 5.55 billion in 2018. Semisynthetic penicillin is commonly used in obstetrics and gynecology for the treatment of surgical prophylaxis, intra-amniotic infection, mastitis, endometritis, and other pelvic infections. For example, amoxicillin, another antibiotic in the penicillin class, works well against syphilis. It is also prescribed for oral infections, ear infections, and pneumonia, among other bacterial infections. It can also work against sinus infections and other lung infections, such as bronchitis.  The increasing usage of semisynthetic strains of penicillin over natural penicillin and the low possibility of resistance to organisms are likely to boost the growth of the semisynthetic penicillin segment in the market during the forecast period.

By Type 

The high market share is attributed to the ease of administration of oral penicillin antibiotics, as well as their lower price when compared with parenteral penicillin antibiotics. Oral penicillin antibiotics are intended to be taken through the mouth, without the need for any special assistance or clinical setting for their administration, unlike parenteral penicillin antibiotics. In addition, oral antibiotics are well tolerated and are associated with lesser side effects when compared with parenteral penicillin antibiotics. Moreover, oral therapy is associated with lesser toxicity, owing to the late onset of action, which permits easier recovery than in the case of other dosage forms, which is expected to fuel the growth of the oral segment in the market during the forecast period.

In some patients, the absorption of penicillin antibiotics from the gastrointestinal tract is less, which leads to unpredictable therapeutic results when treated with oral penicillin antibiotics. Hence, parenteral penicillin antibiotics are given to produce the desired therapeutic outcome. However, parenteral penicillin antibiotics are associated with an increased risk of drug reactions as small doses administered through the intramuscular or intravenous route reach their maximum bioavailability in a shorter period when compared with those administered through the oral route. Thus, a higher dose of the drug is available in parenteral dosage form, which may lead to complications. Additionally, prescribing benzylpenicillin (BP) for outpatient parenteral antimicrobial therapy (OPAT) creates a complex challenge of antimicrobial principle. Thus, to reduce the usage of outpatient parenteral penicillin antibiotics, healthcare professionals rely on medications that are dosed once daily or once a month, which have a broad spectrum that is likely to slightly decline the growth of the market growth during the forecast period. 

By Region

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 31% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional market trends and drivers that will shape the market during the forecast period. Improved healthcare infrastructure and reimbursement policies drive medical treatment uptake, despite the market challenge of increasing generic availability. Cost containment strategies prompt manufacturers to explore growth in regions like Brazil, China, and India. Favorable regulatory initiatives encourage antibiotic development. In the US, antibiotic consumption has declined due to awareness campaigns like Get Smart About Antibiotics Week since 2008, reducing unwanted prescriptions since 2014.

In addition, the US government's action plan, initiated in September 2014, aims to combat antibiotic-resistant bacteria, emphasizing health surveillance and innovative projects funded by the Centers for Disease Control and Prevention. These efforts collectively contribute to the fight against antibiotic resistance, marking positive strides in addressing the issue. Such factors are expected to drive the regional market growth during the forecast period. 

Buy Full Report Now

Penicillin Market Key Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Abbott Laboratories - The company offers penicillin, such as Abbott Penicillin G Potassium tablets, which provide effective solutions for a wide range of bacterial ailments.

AdvaCare Pharma, Aenova Holding GmbH, Astellas Pharma Inc., Canvax Biotech SL, Cipla Ltd., F. Hoffmann La Roche Ltd., Fermenta Biotech Ltd., Focus Technology Co. Ltd., FUJIFILM Corp., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Lupin Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Recipharm AB, Sanofi SA, Viatris Inc., and Wellona Pharma

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market includes antibiotics like Amoxicillin and Ampicillin, effective against bacteria such as Streptococcus pneumoniae and Staphylococcus aureus. Available in various forms like tablets, capsules, solutions, and injections, penicillin treats bacterial infections, including pneumonia and respiratory tract infections. Despite its efficacy, antimicrobial resistance (AMR) poses a challenge, leading to increased R&D efforts in the pharmaceutical industry. Generic penicillin medications offer cost-effective alternatives to brand-name counterparts, ensuring global supply chains even during lockdowns and travel restrictions. Penicillin is classified into natural, semisynthetic, aminopenicillin, and penicillinase-resistant types, with varying spectrums of activity. Our researchers analyzed the market research and growth data with 2023  as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage. 

Key Market Driver

Special regulatory designations driving the quality of penicillin are notably propelling market development. The increased rate of development of multidrug-resistant pathogens, coupled with the limited number of antibiotic drugs available for treatment, led to the development of the GAIN Act by the US FDA, which was introduced in 2012. According to this act, any drug being developed for the treatment of qualified infectious diseases will be granted a QIDP designation. This QIDP designation helps in the attainment of fast-track designation and priority review for the drug. Thus, the drug will be developed at a faster rate and released onto the market. The US FDA provides fast-track designation to drugs used for treating infectious diseases and bacterial infections, addressing unmet medical needs, and leading to the rapid development of medications. This includes drugs derived from raw materials and finished products, such as natural penicillin, semisynthetic penicillin, aminopenicillin, and penicillinase-resistant penicillin, each with its own spectrum of activity, ranging from narrow-spectrum to broad-spectrum penicillin. The designation includes benefits such as the eligibility for priority review for NDA if relevant criteria are met.

For instance, Zerbaxa, a combination of ceftolozane (a previously approved cephalosporin) and tazobactam (a beta-lactamase inhibitor), received QIDP designation and thus received a faster US FDA approval. Many of the generic drugs under development, such as surotomycin, Carbavance (meropenem and vaborbactam), eravacycline, plazomicin, and delafloxacin have received QIDP designation from the US FDA along with the fast-track designation. These designations help in the faster entry of drugs into the market, which will thus boost the growth of the market during the forecast period.

Substantial Market Trends

Increased funding for antibiotic research is an emerging trend shaping market growth. Antibiotic resistance is a growing global concern. Increased funding can support research to understand resistance mechanisms, develop new antibiotics, and enhance existing ones, such as penicillin, to remain effective against evolving bacterial strains. Furthermore, bringing new antibiotics, including variations of penicillin, to market requires rigorous clinical testing. Thus, adequate funding supports these trials, ensuring that new drugs are safe, effective, and ready for widespread use. Currently, a few companies are investing in the discovery and R&D of these drugs. This can be attributed to the increased regulatory guidelines and the decreased profits available from the development of antibiotics.

However, the increase in the number of infections is creating an unmet need in the market. This has led various government and non-governmental institutes to take initiatives for the development of antibiotics such as penicillin by providing the necessary funding to research institutes and companies. For instance, in November 2022, Sandoz announced an additional investment of around USD 54 million to increase European manufacturing capacity for the finished dosage form (FDF) of penicillin, the leading class of antibiotics worldwide. Such funding encourages companies to invest more in antibiotic research, which will thus lead to the growth of the market during the forecast period.

Major Market Challenges

Increasing the launch of generics is a significant challenge hindering market growth. As one of the most widely used antibiotics globally, penicillin's high demand and cost-effectiveness have attracted numerous pharmaceutical companies to manufacture generic alternatives. The introduction of generics has intensified market competition, resulting in declining prices and reduced profit margins for branded penicillin. This scenario compels major pharmaceutical firms to reassess strategies and devise innovative approaches to preserve market share.

Additionally, the growing availability of generics provides healthcare providers and patients with more affordable options, impacting the market dynamics. The launch of an increasing number of generic drugs for treating various infectious diseases contributes to revenue erosion for branded drugs, potentially hindering the market's growth prospects.

Buy Now Full Report

Key Market Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.

 Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Source Outlook
  • Semisynthetic
  • Natural
  Type Outlook
  • Oral
  • Parenteral

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina 
    • Australia 

Market Analyst Overview 

The penicillin drug market faces challenges such as antibiotic drug shortages, export restrictions, and interruptions in services, impacting the supply chain and causing concerns about the treatment of scarlet fever, congenital syphilis, and other bacterial infections. The market witnesses investments in finished dosage form (FDF) penicillins, addressing resistance to antimicrobials. Stringent regulatory frameworks govern novel antibacterials, with a focus on broad-spectrum antibiotics effective against gram-positive and gram-negative bacteria. The spectrum of activity segment encompasses urinary tract infections, gonorrhea, and Pseudomonas aeruginosa infections. Innovative solutions like lactamase inhibitor xeruborbactam aim to combat antibiotic resistance. R&D investments drive product development, considering factors like patent expiry and government regulations. Different types, including aminopenicillin and antipseudomonal penicillin, are administered through various delivery modes in healthcare settings like hospitals and clinics.

Additionally, the market addresses antibiotic drugs' challenges, ensuring a steady supply chain of goods. It tackles infectious diseases like scarlet fever and syphilis, emphasizing the Broad Spectrum Segment's role against gram-positive bacteria. Aminoglycosides combat diseases like meningitis, particularly in the African Meningitis Belt, targeting meningococcal and pneumococcal meningitis. Beta-lactam antimicrobials and novel antibiotics counteract antimicrobial resistance. Penicillium mold, known for its cell wall growth inhibition properties, forms the basis for penicillin. The market explores diverse product types, manufacturing processes, and delivery modes, including oral, intramuscular, and intravenous options. Novel approaches like penicillinase-resistant penicillin showcase synthetic, natural, and semisynthetic processes, ensuring effective treatment against contagious diseases.

Market Scope
Report Coverage	Details
Page number	165
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 5.4%
Market Growth 2024-2028	USD 2.82 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	4.72
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 31%
Key countries	US, Canada, UK, Germany, and China
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	Abbott Laboratories, AdvaCare Pharma, Aenova Holding GmbH, Astellas Pharma Inc., Canvax Biotech SL, Cipla Ltd., F. Hoffmann La Roche Ltd., Fermenta Biotech Ltd., Focus Technology Co. Ltd., FUJIFILM Corp., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Lupin Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Recipharm AB, Sanofi SA, Viatris Inc., and Wellona Pharma
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch